XILIO THERAPEUTICS, INC.
XILIO THERAPEUTICS, INC. logo
XLO

XILIO THERAPEUTICS, INC. (XLO)

$2.30.86%

Market is closed
– opens on 8 PM, 12 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$2.2
Day's Range
$2.54
$2.01
52-Week Range
$16.93
1 month return5.74%
3 month return12.21%
1 year return77.56%
5 year return85.62%

Company Information

Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly-owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX202, a tumor-selective IL-2; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15.
OrganizationXILIO THERAPEUTICS, INC.
Employees74
CEODr. Rene Russo BCPS, Pharm.D, Pharm.D.
IndustryHealthcare

Analyst Recommendation

based on 4 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 4 Wall street analysts offering stock ratings for XILIO THERAPEUTICS, INC.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 813.04%

Current

$2.3

Target

$21.0

Recommendation Trend

Based on 4 analyst

Current1M Ago3M Ago
Buy
4
8
8
Hold
0
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
63.7M
Book Value
$4.61
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-6.56
Wall Street Target Price
21.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
0.53
Enterprise Value
-52288995
Enterprise Value/Revenue
0.0
Enterprise Value/Ebitda
0.62

Technicals

50 Day MA
2.48
200 Day MA
3.77

Institutional Holdings

Bain Capital Life Sciences Investors, LLC

10.21%

FMR Inc

9.18%

Octagon Capital Advisors LP

8.83%

RiverVest Venture Management LLC

5.25%

Rock Springs Capital Management LP

4.96%

Vanguard Group Inc

3.25%

Discover more

Frequently Asked Questions

What is XILIO THERAPEUTICS, INC. share price today?

Can Indians buy XILIO THERAPEUTICS, INC. shares?

How can I buy XILIO THERAPEUTICS, INC. shares from India?

Can Fractional shares of XILIO THERAPEUTICS, INC. be purchased?

What are the documents required to start investing in XILIO THERAPEUTICS, INC. stocks?

What are today’s High and Low prices of XILIO THERAPEUTICS, INC.?

What are today’s traded volumes of XILIO THERAPEUTICS, INC.?

What is today’s market capitalisation of XILIO THERAPEUTICS, INC.?

What is the 52 Week High and Low Range of XILIO THERAPEUTICS, INC.?

How much percentage XILIO THERAPEUTICS, INC. is down from its 52 Week High?

How much percentage XILIO THERAPEUTICS, INC. is up from its 52 Week low?

What are the historical returns of XILIO THERAPEUTICS, INC.?

Who is the Chief Executive Officer (CEO) of XILIO THERAPEUTICS, INC.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*